Document Detail


Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study.
MedLine Citation:
PMID:  22534879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pyoderma gangrenosum (PG) is an important disease with significant complications. The objectives of this study were to determine incidence and mortality of PG and strength of reported associations. A retrospective cohort study was completed using computerized medical records from the General Practice Research Database, a large representative UK database. Patients with PG and three groups of age-, sex-, and practice-matched controls--general population, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) controls--were included in the study. Incidence and mortality were determined and validation undertaken to inform diagnostic accuracy. In all there were 313 people with the median age of 59 (interquartile range 41-72) years, and of them 185 (59%) were female. The adjusted incidence rate standardized to European standard population was 0.63 (95% confidence interval (CI) 0.57-0.71) per 100,000 person-years. The risk of death was three times higher than that for general controls (adjusted hazard ratio=3.03, 95% CI 1.84-4.73, P<0.001), 72% higher than that for IBD controls (adjusted hazard ratio=1.72, 95% CI 1.17-2.59, P=0.013), with a borderline increase compared with RA controls (adjusted hazard ratio=1.55, 95% CI 1.01-2.37, P=0.045). Disease associations were present in 110 (33%) participants: IBD, n=67 (20.2%); RA, n=39 (11.8%); and hematological disorders, n=13 (3.9%). To our knowledge, there are no previous population-based studies of the epidemiology of PG, an important disease with significantly increased mortality.
Authors:
Sinéad M Langan; Richard W Groves; Tim R Card; Martin C Gulliford
Related Documents :
15893179 - Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results f...
15136069 - The relationship between high-sensitive c-reactive protein and pulse wave velocity in h...
22299039 - Hnf1b and endometrial cancer risk: results from the page study.
22783989 - An analysis of c-reactive protein, procalcitonin, and d-dimer in pre-eclamptic patients.
18947439 - Low serum zinc concentrations predict mortality in patients referred to coronary angiog...
22578809 - Trihalomethanes, chlorite, chlorate in drinking water and risk of congenital anomalies:...
2786349 - Self-reported diabetes in mexican americans: hhanes 1982-84.
7071349 - Ossification of the thoracic posterior longitudinal ligament in a fixed population. rad...
20810709 - What role for qlaira in contraception?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-26
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  132     ISSN:  1523-1747     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-20     Completed Date:  2012-11-07     Revised Date:  2014-03-14    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2166-70     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Arthritis, Rheumatoid / epidemiology
Child
Databases, Factual / statistics & numerical data
Female
Great Britain / epidemiology
Hematologic Diseases / epidemiology
Humans
Incidence
Inflammatory Bowel Diseases / epidemiology
Male
Middle Aged
Pyoderma Gangrenosum / epidemiology*,  mortality
Retrospective Studies
Risk
Young Adult
Grant Support
ID/Acronym/Agency:
NIHR/CS/010/014//Department of Health

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Array comparative genomic hybridization of keratoacanthomas and squamous cell carcinomas: different ...
Next Document:  A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and...